Hepatitis C Draft Guidance Cites Utility Of Unapproved HCV-RNA Tests
This article was originally published in The Gray Sheet
Executive Summary
Clinical trials of hybridization assays for monitoring hepatitis C viral RNA may use other unapproved HCV-RNA assays to corroborate test results, provided supporting data is submitted, FDA indicates in a recently released draft guidance.
You may also be interested in...
HEPATITIS C RNA PANEL SHOULD BE DEVELOPED TO TEST NEW ASSAYS, PANEL SAYS; DCLD DEVELOPING GUIDANCE ON VARIOUS HEPATITIS A, B, C TESTS AND INDICATIONS
FDA should develop a panel of hepatitis C virus RNA specimens to challenge new qualitative HCV RNA assays, the agency's Microbiology Devices Panel recommended at its Feb. 12 meeting in Gaithersburg, Maryland. The group was convened to assist FDA's Center for Devices and Radiological Health in efforts to develop a guidance that will prescribe clinical study guidelines for hepatitis A, B, or C tests for diagnosis and/or monitoring indications.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.